Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 10Neutropenia 8Breast Neoplasms 8Leukemia, Myeloid, Acute 7Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 4Febrile Neutropenia 4Leukemia, Monocytic, Acute 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Osteosarcoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Myeloid 1Sarcoma, Clear Cell 1Rhabdoid Tumor 1Retinoblastoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Etoposide 9Rituximab 8Cyclophosphamide 7Vincristine 6Prednisone 6Doxorubicin 5Filgrastim 4Cytarabine 3Radiotherapy 2Procarbazine 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lomustine 2Carmustine 2prednylidene 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1ibrutinib 1ibritumomab tiuxetan 1etoposide phosphate 1efavirenz 1deltacortene 1VAP-cyclo protocol 1Ultrasonography 1Radioimmunotherapy 1Ondansetron 1O(6)-benzylguanine 1Mitoguazone 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, AIDS-Related × pegylated granulocyte colony-stimulating factor × Clear all
NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
46 enrolled 19 charts
Lymphoid

Lymphoma, AIDS-Related

Data powered by HemOnc (CC BY 4.0) Colophon âš¡